Osteoprotective Effect of the Phytonutraceutical Ormona® on Ovariectomy-Induced Osteoporosis in Wistar Rats

The phytonutraceutical Ormona® is a product composed of purified oil of Bixa orellana Linné, dry extract of Myrciaria dubia McVaugh, dry extract of Trifolium pratense L., and dry extract of Euterpe oleracea Mart. obtained using Evolve® technology. This study evaluated the effects of Ormona® on Wistar rats affected by ovariectomy-induced osteoporosis. Pre-treatment was conducted for 15 days before surgery and continued for a further 45 days after the surgical procedure. The experimental design consisted of five groups (n = 5): OVW: treated with distilled water (1 mL/kg, p.o); ADS: alendronate sodium (4 mg/kg p.o); EST: conjugated estrogen (2 µg/kg, p.o); ORM: Ormona® (20 mg/kg, p.o); ORM + EST: Ormona® (20 mg/kg, p.o) + conjugated estrogen (2 µg/kg, p.o). Biochemical and hormonal parameters of bone histopathology and trabecular and femoral diaphysis size were evaluated through scanning electron microscopy (SEM) and bone calcium quantification by atomic absorption spectrophotometry. The results show that ovariectomy caused bone alterations such as loss of femoral microarchitecture, decreased bone homeostasis parameters, and changes in the lipid profile. Estrogen supplementation reduced parameters such as cholesterol, LDL, and Ca2+ concentration. However, Ormona® showed higher serum estradiol levels (p < 0.01), effects on the lipid profile, including parameters that estrogen replacement and alendronate sodium did not affect, with an increase in HDL, and positive modulation of bone metabolism, increasing osteocytes and the presence of osteoblasts. Ormona®, therefore, produced better results than the groups treated with estrogen and alendronate sodium.